title: Brain "ouabain" and angiotensin II contribute to cardiac dysfunction after myocardial infarction.
abstract: In chronic heart failure (CHF), sympathetic activity increases in parallel with the impairment of left ventricle (LV) function, and sympathetic hyperactivity has been postulated to contribute to the progression of heart failure. In the brain, compounds with ouabain-like activity ("ouabain," for brevity) and the renin-angiotensin system contribute to sympathetic hyperactivity in rats with CHF after myocardial infarction (MI). In the present studies, we assessed whether, in rats, chronic blockade of brain "ouabain" or the brain renin-angiotensin system inhibits the post-MI LV dysfunction. In rats, an MI was induced by acute coronary artery ligation. At either 0.5 or 4 wk post-MI, chronic treatment with Fab fragments for blocking brain "ouabain" or with losartan for blocking brain AT(1) receptors was started and continued until 8 wk post-MI using osmotic minipumps connected to intracerebroventricular cannulas. At 8 wk post-MI, in conscious rats, LV pressures were measured at rest and in response to volume and pressure overload, followed by LV passive pressure-volume curves in vitro. At 8 wk post-MI, control MI rats exhibited clear increases in LV end-diastolic pressure (LVEDP) at rest and in response to pressure and volume overload. LV pressure-volume curves in vitro showed a marked shift to the right. Intravenous administration of the Fab fragments or losartan at rates used for central blockade did not affect these parameters. In contrast, chronic central blockade with either Fab fragments or losartan significantly lowered LVEDP at rest (only in 0.5- to 8-wk groups) and particularly in response to pressure or volume overload. LV dilation, as assessed from LV pressure-volume curves, was also significantly inhibited. These results indicate that chronic blockade of brain "ouabain" or brain AT(1) receptors substantially inhibits development of LV dilation and dysfunction in rats post-MI.
authors.affiliation: Hypertension Unit, University of Ottawa Heart Institute, Ottawa, Ontario, Canada K1Y 4W7. fleenen@ottawaheart.ca
authors.forename: F H
authors.initials: FH
authors.lastname: Leenen
authors.forename: B
authors.initials: B
authors.lastname: Yuan
authors.forename: B S
authors.initials: BS
authors.lastname: Huang
mesh_terms: D000804:Angiotensin II / Q000502:physiology*; D000818:Animals; D001794:Blood Pressure; D001810:Blood Volume; D001921:Brain / Q000378:metabolism*; D002298:Cardenolides / Q000378:metabolism*; D006027:Glycosides / Q000502:physiology*; D006321:Heart / Q000503:physiopathology*; D006439:Hemodynamics; D006940:Hyperemia / Q000503:physiopathology; D006973:Hypertension / Q000503:physiopathology; D066298:In Vitro Techniques; D008297:Male; D009203:Myocardial Infarction / Q000503:physiopathology*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D002298:Cardenolides; D006027:Glycosides; D000804:Angiotensin II